News
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
15h
MoneyWeek on MSNCash in on the biotech boom with three promising European picksAilsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from ...
Mount Marty University will launch the region’s first Graduate Regulatory Science Program to train future leaders in the ...
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up ...
AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional ...
12h
WISH-TV on MSNPurdue's new research center revolutionizes pharmaceutical innovationPurdue University's College of Pharmacy has partnered with Stony Brook University to bring the Center for Research Innovation in Biotechnology and its Clinical Drug Experience Knowledgebase to the ...
19h
Vietnam Investment Review on MSNGuanHe and LabConnect sign deal to transform lab servicesTeddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services. The two parties will jointly build ...
PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...
Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results